title stringlengths 1 1.19k | keywords stringlengths 0 668 | concept stringlengths 0 909 | paragraph stringlengths 0 61.8k | PMID stringlengths 10 11 |
|---|---|---|---|---|
3.7. Adverse Events | gastrointestinal reactions, nausea, vomiting, constipation, dizziness, GI TEAEs, TEAE | ADVERSE EVENTS, LOSS OF APPETITE | Neither fatalities nor severe adverse events happened during the research. The adverse event-related discontinuation rate was 2.94% (2/68) in both groups. Two participants developed gastrointestinal reactions within the first week of starting dulaglutide injection; therefore, they were unwilling to continue to dulaglut... | PMC9920202 |
4. Discussion | T2D, PCOS, weight reduction, overweight, Diabetes, weight loss | ADVERSE EVENTS, EVENTS, OBESE, DIABETES | Participants in the dulaglutide + CRD group took a shorter time to achieve a 7% weight loss goal than those in the CRD group, which suggests that dulaglutide could favor high efficiency in achieving the target weight loss. This finding was generally supported by the results of previous studies that have demonstrated th... | PMC9920202 |
5. Conclusions | RA, overweight, weight loss, PCOS | OBESE | In our study, for an identical degree of weight loss, dulaglutide combined with a CRD regimen did not produce a more pronounced reduction in visceral fat than the CRD regimen. Dulaglutide combined with CRD could favor high efficiency in achieving targeted weight loss and provide additional benefits in terms of the HbA1... | PMC9920202 |
Supplementary Materials | The following supporting information can be downloaded at: Click here for additional data file. | PMC9920202 | ||
Author Contributions | Conceptualization, M.Z.; Formal analysis, Y.Z.; Investigation, Y.Z., Z.Q. and T.L.; Resources, Z.Q., T.L., X.S., M.C., D.D., X.G., W.M. and F.H.; Data curation, Y.Z., X.S., M.C., D.D. and X.G.; Writing—original draft, Y.Z. and M.Z.; Writing—review and editing, T.H., S.Q. and M.Z.; Visualization, L.S. and Q.L.; Supervis... | PMC9920202 | ||
Institutional Review Board Statement | The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Shanghai Tenth People’s Hospital (approval number SHSY-IEC-4.1/21-119/01). | PMC9920202 | ||
Informed Consent Statement | Written informed consent was obtained from all participants. | PMC9920202 | ||
Data Availability Statement | All data generated or analyzed during this study are available from the corresponding authors on reasonable request. | PMC9920202 | ||
Conflicts of Interest | The authors declare no conflict of interest. | PMC9920202 | ||
References | liver stiffness, PCOS,, weight loss, polycystic ovary syndrome | ADVERSE EVENT, INSULIN RESISTANCE, ADVERSE EVENT | Flow diagram of this randomized, controlled, open-label trial. CRD, calorie-restricted diet. RCT, randomized controlled trial.Time-to-event analysis of achieving 7% weight loss of initial body weight in the two groups. CRD, calorie-restricted diet; HR, hazard ratio.The change in VAT area from baseline to reach 7% weigh... | PMC9920202 |
Abstract | PMC10028154 | |||
Background | Survivorship care plans (SCPs) communicate cancer‐related information from oncology providers to patients and primary care providers. SCPs may limit overuse testing by specifying necessary follow‐up care. From a randomized, controlled trial of SCP delivery, we examined whether cancer‐related tests not specified in SCPs... | PMC10028154 | ||
Methods | breast, colorectal, or prostate cancer | REGRESSION | Survivors of breast, colorectal, or prostate cancer treated at urban‐academic or rural‐community health systems were randomized to one of three SCP delivery arms. Tests during 18 months after SCP receipt were classified as consistent with overuse if they were (1) not included in SCPs and (2) on a guideline‐based predet... | PMC10028154 |
Results | colorectal, 112 prostate), tumor, breast cancer | TUMOR, BREAST CANCER | Among 316 patients (137 breast, 67 colorectal, 112 prostate), 140 individual tests were identified as potential overuse. Upon review, 98 were deemed to be consistent with overuse: 78 tumor markers and 20 imaging tests. The majority of overuse testing was breast cancer‐related (95%). Across sites, 27 patients (9%) recei... | PMC10028154 |
Conclusions | cancer, Cancer | CANCER, CANCER | This analysis identified practice patterns consistent with overuse of surveillance testing and can inform efforts to improve guideline‐concordant care. Future interventions may include individual practice patterns and provider education.Cancer survivors at both academic and community cancer centers experienced overuse ... | PMC10028154 |
INTRODUCTION | cancer, prostate cancer, breast, colorectal, and | CANCER, PROSTATE CANCER | With the aging population and advances in early cancer detection and treatment, the number of cancer survivors now exceeds 16 million in the United States.Surveillance patterns are likely influenced by factors at multiple levels, including the health system, patient, and provider levels. From a randomized, controlled t... | PMC10028154 |
METHODS | PMC10028154 | |||
Study population | breast, colorectal, or prostate cancer | ONCOLOGY, DISEASE | Patients recruited in this study were survivors of newly diagnosed or recurrent Stages I‐III breast, colorectal, or prostate cancer who were being treated at one of the two sites: (1) an urban, academic tertiary medical center with multiple oncology programs based on disease site and (2) a rural, regional community med... | PMC10028154 |
Data collection | tumor, Cancer | TUMOR, BREAST CANCER, PROSTATE, ONCOLOGY, CANCER | For each patient, we collated the laboratory and imaging tests performed during the 18 months after SCP receipt that were predetermined in the study protocol as “not recommended surveillance” (Table Surveillance testing recommendations for Stages I–III Cancer predetermined for the study protocolEvery 3–6 months: CEAAnn... | PMC10028154 |
Statistical analysis | REGRESSION | To be included in this analysis, patients had to receive an SCP and complete 18 months of follow‐up. We performed a descriptive analysis of tests ordered outside of SCPs, including frequency and percentage of tests consistent with overuse, and patients with testing consistent with overuse. Negative binomial regression ... | PMC10028154 | |
RESULTS | tumor, abnormal tumor, lymphadenopathy | TUMOR, RECRUITMENT, LYMPHADENOPATHY | Among 316 patients in the study, a total of 282 tests were ordered that were not indicated in SCP recommendations (Figure Results of adjudication by chart review across both sites (Age < 50 at diagnosis or dense/heterogeneous tissue (15, 71%)Recommended follow‐up (2, 10%)Workup for symptoms (1, 5%)Symptoms (1, 9%)Surve... | PMC10028154 |
Overuse testing by recruitment site and tumor type | tumor, colorectal, breast cancer, cancer, cancer type | CANCER, TUMOR, BREAST CANCER | Of the 140 cancer‐related tests ordered that were not recommended on SCPs (including tumor markers), 91% (90/99) at the community site were consistent with overuse and 20% (8/41) at the academic site were consistent with overuse. The majority of testing consistent with overuse at the community site (78/90, 87%) was rel... | PMC10028154 |
Overuse testing at the patient level | cancer type, tumor, breast cancer | TUMOR, BREAST CANCER | From the 316 patients in the study (137 breast, 67 colorectal, 112 prostate), 111 patients had tests that were identified for review as potential overuse. After excluding non‐cancer‐related tests, 53 patients had at least one cancer‐related test that needed adjudication for overuse. Some patients had multiple tests ord... | PMC10028154 |
DISCUSSION | tumor, colorectal, and, Tumor, breast cancer, breast, colorectal, and prostate cancer, cancer, Two‐thirds, prostate cancer, Cancer | TUMOR, TUMOR, BREAST CANCER, CANCER, ONCOLOGY, PROSTATE CANCER, CANCER | We assessed the appropriateness of cancer‐related testing not recommended in the SCPs of early‐stage breast, colorectal, and prostate cancer survivors enrolled in a trial of SCP delivery. We accounted for provider reasons for test ordering based on documentation in the medical record, although surveying providers would... | PMC10028154 |
AUTHOR CONTRIBUTIONS | PMC10028154 | |||
FUNDING INFORMATION | Cancer | CANCER | This study was funded through a PCORI Award (IHS‐1409‐22534). The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins receives funding from the National Cancer Institute (P30CA006973). | PMC10028154 |
CONFLICT OF INTEREST | All authors received Patient‐Centered Outcomes Research Institute (PCORI) research funding through their institution. Dr. Sheng has received Pfizer research funding through her institution. Dr. Snyder has received personal royalties for section authorship in up‐to‐date, personal consulting fees from Janssen (via Health... | PMC10028154 | ||
ETHICS STATEMENT | The study complies with the Declaration of Helsinki and was approved by the Institutional Review Board at the Johns Hopkins School of Medicine. All patients provided their written informed consent. | PMC10028154 | ||
DISCLAIMERS | The statements in this publication are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee. | PMC10028154 | ||
ACKNOWLEDGMENTS | We thank the Simplifying Survivorship Care Planning Stakeholder Advisory Board for their feedback and contributions throughout the study. | PMC10028154 | ||
DATA AVAILABILITY STATEMENT | The datasets generated and analyzed during the current study are available from the corresponding author on request | PMC10028154 | ||
REFERENCES | PMC10028154 | |||
Subject terms | IBS, LPADC, lung papillary adenocarcinoma | REGRESSION | Accurate prognostic prediction is crucial for treatment decision-making in lung papillary adenocarcinoma (LPADC). The aim of this study was to predict cancer-specific survival in LPADC using ensemble machine learning and classical Cox regression models. Moreover, models were evaluated to provide recommendations based o... | PMC10491759 |
Introduction | Lung cancer, death, tumor | REGRESSION, LUNG ADENOCARCINOMA, LUNG CANCER, TUMOR | Lung cancer remains the leading cause of cancer-related death worldwide, accounting for approximately 1.8 million deathsDue to the rarity of LPADC, most currently available studies are case reports or single-center small-sample investigations. The 5-year overall survival rate of LPADC patients is less than 35%, and Cox... | PMC10491759 |
Materials and methods | PMC10491759 | |||
Patient selection | ONCOLOGY, DISEASES | The SEER*Stat version 8.4.0 (Screening process for the selection of patients. ICD-O-3, International Classification of Diseases for Oncology (Third Edition). | PMC10491759 | |
Cohort definition and variables | tumor | TUMOR | We randomly classified the study sample into the training and validation cohorts using a 7:3 ratio. The training and validation cohorts were used to construct and verify the model, respectively. Fourteen variables from the SEER database were included in the study model, including demographic variables (age at diagnosis... | PMC10491759 |
Model development | Categorical variables were collated in frequency and percentage format, and differences between groups were compared using the χ | PMC10491759 | ||
Ethics statement | The SEER database is free for researchers to download and therefore does not require ethical review by the authors’ institution. | PMC10491759 | ||
Results | PMC10491759 | |||
Feature importance | tumor, T4 stage | TUMOR | The feature importance plot shows the contribution of each feature in the prognostic model. N2 stage, M1 stage, and no surgery occupied the top three positions in the feature importance ranking; this ranking was consistently observed across the four models. In the CoxPH model, T4 stage, and tumor primary location (lowe... | PMC10491759 |
Algorithm deployment | tumor | TUMOR | The constructed models for determining the CSS rate of patients with LPADC were deployed on a web page. The functionality of the application and the visualization of the output are shown in the following Fig. Interface display of web calculator. A patient with LPADC aged < 79, male, black, left-sided lung, T1N0M0 stage... | PMC10491759 |
Discussion | pulmonary papillary carcinoma, tumor, GBS | TUMOR, METASTASES | The accurate prediction of survival in patients with LPADC is essential for patient counseling, follow-up, and treatment planning. Previous studies have revealed multiple prognostic factors that affect the survival time of patients with pulmonary papillary carcinoma, including patient age, grade classification, lymph n... | PMC10491759 |
Supplementary Information | The online version contains supplementary material available at 10.1038/s41598-023-40779-1. | PMC10491759 | ||
Author contributions | L.L.: designing and guidance. K.X. and S.J.: software analysis and writing the draft. X.Y. and D.C.: reviewing and editing. All authors have read and agreed to the published version of the manuscript. All authors have contributed to the article and approved the submission. | PMC10491759 | ||
Data availability | The original contributions presented in the study are included in the article, further inquiries can be download from | PMC10491759 | ||
Competing interests | The authors declare no competing interests. | PMC10491759 | ||
References | PMC10491759 | |||
Background | Acquiring adequate theoretical knowledge in the field of dental radiography (DR) is essential for establishing a good foundation at the prepractical stage. Currently, nonface-to-face DR education predominantly relies on two-dimensional (2D) videos, highlighting the need for developing educational resources that address... | PMC10642063 | ||
Methods | Forty-four participants were randomly assigned to a control group (n = 23; 2D video) and an experimental group (n = 21; 360° VR). DR was re-enacted by the operator and recorded using 360° video. A survey was performed to assess learning satisfaction and self-efficacy. The nonparametric statistical tests comparing the g... | PMC10642063 | ||
Results | Learners in the experimental group could experience VR for DR by attaching their smartphones to the pHMD. The 360° VR video with pHMD provided a step-by-step guide for DR learning from the point of view of an operator as VR. Learning satisfaction and self-efficacy were statistically significantly higher in the experime... | PMC10642063 | ||
Conclusions | The 360° VR videos were associated with greater learning satisfaction and self-efficacy than conventional 2D videos. However, these findings do not necessarily substantiate the educational effects of this medium, but instead suggest that it may be considered a suitable alternative for DR education in a nonface-to-face ... | PMC10642063 | ||
Keywords | PMC10642063 | |||
Background | coronavirus disease 2019 | DENTAL DISEASES, CORONAVIRUS DISEASE 2019 | Oral radiographs offer valuable diagnostic insights into dental diseases and conditions [The coronavirus disease 2019 (COVID-19) pandemic has made it difficult to conduct face-to-face classes, and digital education is compulsory [There is a demand for a digital education strategy that uses VR technology to facilitate 3... | PMC10642063 |
Methods | PMC10642063 | |||
Research design | HMD | RECRUITMENT | This randomized controlled trial compared the control and experimental groups in a dental radiology class. To provide a VR experience using pHMD on a smartphone, we produced a 360° video for DR that can be played on a mobile device. The operator (dental hygienist; 17 years of DR experience) who performed DR wore a helm... | PMC10642063 |
Recruitment of participants | RECRUITMENT | A recruitment notice was posted on the online bulletin board for students taking dental radiology in the 2nd year of the Department of Dental Hygiene at Samhyook University in 2021. Students who voluntarily wanted to participate were recruited for 1 week. The notification specifies that the participants’ academic grade... | PMC10642063 | |
Survey tool for comparison between groups | Wang et al.’s [
Survey questions on learning satisfaction and self-efficacyL: Learning satisfaction; S: Self-efficacy | PMC10642063 | ||
Statistical analysis | The self-administered questionnaire was designed to enable the assessment of agreement levels using a 5-point Likert scale. Learning satisfaction was assessed once after exposure to the relevant medium, while self-efficacy was measured twice before and after exposure to ensure group homogeneity. The same questionnaire ... | PMC10642063 | ||
Results | By clicking the VR icon in the YouTube application, DR image recorded in 360° on the smartphone was divided into left and right. The participants could experience VR after playing the video by attaching the smartphone to the pHMD. Figure
Dental radiography learning tool based on virtual reality. (
360° video according... | PMC10642063 | ||
Discussion | Self-learning tools aimed at facilitating independent learning among students are essential in the field of dental education [Furthermore, among advanced VR technologies, the use of mixed-reality technology using Microsoft’s HoloLens provides an augmented and virtual experience in dental education and is highly effecti... | PMC10642063 | ||
Conclusions | The current study utilized 2D and 360° VR videos to develop learning mediums that enabled virtual DR education in a nonface-to-face learning environments. The participants underwent VR learning using their smartphones and pHMDs, and their levels of learning satisfaction and self-efficacy were assessed using surveys. Th... | PMC10642063 | ||
Acknowledgements | We sincerely thank the dental hygiene students who actively participated in this experiment. | PMC10642063 | ||
Authors’ contributions | JE performed creation of virtual reality based-education tool using 360° video and prefabricated head-mounted display, data acquisition, data analysis and draft manuscript. JY contributed to major writing the manuscript, review and correction of video, statistical interpretation, photographic works, and providing educa... | PMC10642063 | ||
Funding | This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (NRF-2020R1I1A3061952). | PMC10642063 | ||
Data Availability | The datasets utilized in this study can be obtained by contacting the corresponding author through a reasonable request. | PMC10642063 | ||
Declarations | PMC10642063 | |||
Ethics approval and consent to participate | This study was approved by the Institutional Review Board of Namseoul University (No: 202102-003). All the protocols conform to the Declaration of Helsinki–ethical principles for medical research involving human subjects and the authors confirmed this. None of the authors have financial or private relationships with an... | PMC10642063 | ||
Consent for publication | Not applicable. | PMC10642063 | ||
Competing interests | The authors declare no competing interests. | PMC10642063 | ||
References | PMC10642063 | |||
Background | inflammation, head and neck cancer, HNC | ORAL MUCOSITIS, ORAL MUCOSITIS, INFLAMMATION, DISEASES, ORAL ULCERATIONS, HEAD AND NECK CANCER, SEQUELAE | Oral mucositis (OM) is recognized as one of the most frequent debilitating sequelae encountered by head and neck cancer (HNC) patients treated by radiotherapy. This results in severe mucosal tissue inflammation and oral ulcerations that interfere with patient’s nutrition, quality of life (QoL) and survival. Omega-3 (ω-... | PMC10470147 |
Materials and methods | MDASI-HN, head and neck cancer, Head and Neck cancer, pain | HEAD AND NECK CANCER, ORAL MUCOSITIS | Thirty-four head and neck cancer patients planned to receive radiotherapy were randomly allocated into two groups: Group I: conventional preventive treatment and Group II: topical Omega-3 nanoemulgel. Patients were evaluated at baseline, three and six weeks after treatment using the World Health Organization (WHO) grad... | PMC10470147 |
Results | mucositis | MUCOSITIS | VAS scores and WHO mucositis grades were significantly lower after six weeks of treatment with topical Omega-3 nanoemulgel when compared to the conventional treatment. The total MDASI score was significantly higher in the control group after three weeks of treatment, and the head and neck subscale differed significantl... | PMC10470147 |
Conclusions | ORAL MUCOSITIS | Topical Omega-3 nanoemulgel demonstrated a beneficial effect in prevention of radiation-induced oral mucositis with a possibility of regulating oral microbial dysbiosis. | PMC10470147 | |
Keywords | Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC10470147 | ||
Background | chemotherapy-, diabetes, cardiovascular diseases, gingivitis, HNC, pain, dehydration, intestinal microbial dysbiosis, head and neck cancer | ORAL MUCOSITIS, ORAL MUCOSITIS, MALNUTRITION, RECURRENT APHTHOUS STOMATITIS, INFLAMMATION, DISEASE, DISEASES, GINGIVITIS, PERIODONTAL DISEASES, DEHYDRATION, PATHOGENESIS, HEAD AND NECK CANCER, ULCERATION, MUCOSAL INFLAMMATION, ULCERATIONS, SECONDARY INFECTION, COMPLICATIONS | Oral mucositis (OM) is considered one of the most common debilitating complications that develops in head and neck cancer (HNC) patients receiving radiotherapy [Radiation-induced oral mucositis (RIOM) is described as an injury to normal tissues occurring in the form of oral mucosal inflammation and/or ulceration, encou... | PMC10470147 |
Materials and methods | PMC10470147 | |||
Study design | head and neck cancer, thirty-four | ONCOLOGY, HEAD AND NECK CANCER | A two-arm parallel randomized, controlled clinical trial was conducted on thirty-four head and neck cancer patients of both genders who were planned to receive radiotherapy from February to September 2022. Patients were selected from the outpatient clinic of Department of Clinical Oncology, Faculty of Medicine, Alexand... | PMC10470147 |
Participants | septic, malignancy, head and neck cancer, caries | HEAD AND NECK CANCER, CARIES | Participants were eligible if they had head and neck cancer proven malignancy and were planned to receive radiotherapy (50 Gy or above) using machine (Elekta unity linear accelerator, Sweden) [Before enrollment in the study, thorough medical and dental history was taken from all patients. All participants received phas... | PMC10470147 |
Sample size estimation | Sample size was estimated assuming 5% alpha error and 80% study power. Bakr et al. [ | PMC10470147 | ||
Randomization, blinding and allocation concealment | Randomization was performed using a computer-generated random allocation software [ | PMC10470147 | ||
Preparation of Omega-3 nanoemulgel | Fish oil (Omega-3 fatty acids 70.4%; EPA 34.9% and DHA 24.2%) was supplied from Safe pharmaceutical company, Alexandria, Egypt. To enhance fish oil ingredients’ absorption and tissue-penetration, Omega-3 nanoemulgel was formulated [ | PMC10470147 | ||
Intervention | thirty-four | The assigned thirty-four patients were randomly allocated to the following groups:The control group (n = 17) received conventional preventive treatment that was started one day before radiotherapy and applied twice daily for six weeks [The test group (n = 17) were given topical Omega-3 nanoemulgel formulated and charac... | PMC10470147 | |
Outcome measures | Pain | ORAL MUCOSITIS | As patients were planned to receive a typical radiation cycle of (5–7) weeks, and as OM clinical signs usually appear by the second or third week of treatment [
Oral mucositis severity, measured using the WHO grading system [Pain and discomfort were reported by each patient using the Visual Analog Scale (VAS) [Symptom ... | PMC10470147 |
Microbiological assessment | PMC10470147 | |||
Sample collection, preservation, and transport | STERILE | Oral samples were collected from all patients using sterile cotton tipped swabs which were used to remove saliva and shedded cells by gently scrapping the oral mucosa. Swabs were then put into 3 ml sterile phosphate buffered saline (PBS) and were immediately delivered and stored at − 20 °C, at Alexandria University Dia... | PMC10470147 | |
DNA extraction | DNA was extracted from samples using QIAamp® DNA Mini Kit (QIAGEN, Hilden, Germany) according to the manufacturers’ instructions. DNA extracts were stored at − 80 °C until PCR testing. Eight microliters of DNA extract were used for each PCR reaction. | PMC10470147 | ||
Real-time PCR (SYBR green) | The real-time PCR protocol was done as previously described [
Primers’ sequences used in the current studyCGCTAGTAATCGTGGATCAGAATGTGTGACGGGCGGTGTGTAGTTTAATTCGATGATACGCGAGTTAASCCGACACCTCACGG | PMC10470147 | ||
Statistical analysis | Data were analyzed using IBM SPSS for Windows (Version 23.0) and significance was inferred at p value < 0.05. Descriptive statistics were calculated as means, standard deviation (SD), median, interquartile range (IQR), frequencies and percentages. Comparisons between the two study groups were done using independent sam... | PMC10470147 | ||
Discussion | oral mucositis, head and neck cancer, mucositis, dysbiosis, head and neck tumours | ORAL MUCOSITIS, MOUTH SORES, HEAD AND NECK CANCER, MUCOSITIS, DISEASES, COMPLICATIONS | RIOM is one of the most frequently encountered complications in HNC [Our results are aligned with Hashemipour et al. [Although clinician-reported instruments such as the WHO grading system can provide an adequate estimate of the severity of oral mucositis and its associated symptoms, patient reported outcome tools have... | PMC10470147 |
Conclusions | pain | The current study demonstrated a beneficial effect of topical use of ω-3 nanoemulgel in RIOM prevention, decreasing the associated pain intensity and improving the overall QoL of HNC patients. Moreover, in addition to its potent anti-inflammatory and antioxidant properties, our study suggests a potential role of Omega-... | PMC10470147 | |
Acknowledgements | The authors would like to show grateful recognition to Dr Hossam Elsabagh and Dr Farida Reyad (Oral Medicine, Periodontology, Oral Diagnosis, and Oral Radiology Department, Alexandria University) for their contribution in the professional writing. The authors are indebted to Dr Mahmoud Khodir (Oral and Maxillofacial Su... | PMC10470147 | ||
Author contributions | BMM contributed to research idea, study design, dataacquisition, and interpretation, drafted and critically revised the manuscript.SD contributed to study design, data interpretation, and critically revised the manuscript. MAMM contributed to study design, patients’ selection, data analysis and critically revised the m... | PMC10470147 | ||
Funding | The authors did not receive any funding for this study.Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). | PMC10470147 | ||
Data Availability | All data included in this study are available from the corresponding author upon request. | PMC10470147 | ||
Declarations | PMC10470147 | |||
Ethics approval and consent to participate | Ethical approval for the study was obtained from the Research Ethics Committee at the Faculty of Dentistry, Alexandria University (IRB 00010556)- (IORG 0008839). A detailed informed consent was provided by each patient. | PMC10470147 | ||
Consent for publication | Not applicable. | PMC10470147 | ||
Competing interest | The authors declare they have no conflict of interest. | PMC10470147 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.